Boehringer Ingelheim Acquires Fourth License for the Development of Novel Antibody Based Cancer Treatments from Oxford BioTherapeutics
Oxford, UK and San Jose, California, 9 January 2024 - (OBT), a clinical stage oncology company with a pipeline of ...
FierceBiotech6h
Lonza's Synaffix adds Boehringer to its constellation of partners with $1.3B ADC tech pact
After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking ...
Samsung Biologics and LigaChem extend ADC services deal
Samsung Biologics has extended its collaboration with LigaChem Biosciences for antibody-drug conjugate (ADC) services. The ...
Le Lézard4h
Biocytogen Announces Licensing of Fully Human Antibodies with SOTIO to Develop Novel ADC SOT109 for Colorectal Cancer Treatment
Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its fully human antibodies to SOTIO Biotech, a ...
Armed robbery in Revesby4h
Biocytogen Licenses Antibodies to SOTIO for Cancer Drug
Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its ...
FierceBiotech5h
Fierce Biotech Layoff Tracker 2025: Scribe slims workforce by 20%; Galapagos lays off 300 staffers
We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...
Hosted on MSN22h
Chugai and Araris enter $780m ADC research collaboration
Araris will use its linker technology to generate multi-warhead ADCs for “undisclosed targets” provided by Chugai.
Le Lézard16h
Intel to Report Fourth-Quarter and Full-Year 2024 Financial Results
Intel Corporation today announced that it will report fourth-quarter and full-year 2024 financial results on Thursday, Jan. 30, 2025, promptly after close of market. Intel will then hold an earnings ...
BioWorld23h
Sana soars on favorable type 1 diabetes phase I data
Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...